CONMED (NYSE:CNMD) Releases FY 2025 Earnings Guidance

Key Points

• CONMED has provided its FY 2025 earnings guidance, with EPS projected between 4.400-4.550, surpassing the consensus estimate of 4.395.
• The company recently declared a quarterly dividend of $0.20, resulting in an annual yield of 1.59%.
• Several research analysts have downgraded CONMED's rating to "hold," with target prices ranging from $55.00 to $62.20.

CONMED (NYSE:CNMD - Get Free Report) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided EPS guidance of 4.400-4.550 for the period, compared to the consensus EPS estimate of 4.395. The company issued revenue guidance of $1.4 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion.

CONMED Stock Up 2.2%

Shares of CNMD stock traded up $1.10 on Friday, hitting $52.25. The company's stock had a trading volume of 626,071 shares, compared to its average volume of 478,123. The company has a debt-to-equity ratio of 0.91, a current ratio of 2.26 and a quick ratio of 1.00. CONMED has a fifty-two week low of $46.00 and a fifty-two week high of $78.19. The firm's fifty day moving average price is $53.08 and its 200-day moving average price is $57.65. The stock has a market capitalization of $1.62 billion, a price-to-earnings ratio of 14.80, a P/E/G ratio of 1.29 and a beta of 1.20.

CONMED (NYSE:CNMD - Get Free Report) last released its earnings results on Wednesday, July 30th. The company reported $1.15 earnings per share for the quarter, topping analysts' consensus estimates of $1.13 by $0.02. The firm had revenue of $342.35 million during the quarter, compared to analyst estimates of $338.42 million. CONMED had a net margin of 8.31% and a return on equity of 14.60%. The business's revenue was up 3.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.98 EPS. Research analysts anticipate that CONMED will post 4.35 EPS for the current year.

CONMED Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, July 3rd. Investors of record on Friday, June 13th were paid a $0.20 dividend. The ex-dividend date of this dividend was Friday, June 13th. This represents a $0.80 dividend on an annualized basis and a yield of 1.5%. CONMED's payout ratio is presently 22.66%.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Needham & Company LLC cut shares of CONMED from a "buy" rating to a "hold" rating and set a $61.00 target price on the stock. in a research note on Thursday, June 12th. JPMorgan Chase & Co. decreased their price objective on shares of CONMED from $70.00 to $58.00 and set a "neutral" rating on the stock in a research note on Thursday, May 1st. Stifel Nicolaus cut shares of CONMED from a "buy" rating to a "hold" rating and decreased their price objective for the stock from $75.00 to $55.00 in a research note on Monday, April 28th. Piper Sandler reduced their target price on shares of CONMED from $80.00 to $68.00 and set an "overweight" rating on the stock in a research report on Thursday. Finally, Wall Street Zen lowered shares of CONMED from a "buy" rating to a "hold" rating in a research report on Tuesday, May 6th. Five research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $59.80.

Insider Transactions at CONMED

In other news, Director Charles Farkas sold 4,000 shares of the firm's stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $56.94, for a total value of $227,760.00. Following the completion of the transaction, the director directly owned 16,346 shares in the company, valued at approximately $930,741.24. This trade represents a 19.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 3.10% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in CNMD. AQR Capital Management LLC raised its stake in shares of CONMED by 19.9% during the first quarter. AQR Capital Management LLC now owns 14,199 shares of the company's stock worth $857,000 after acquiring an additional 2,357 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of CONMED by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,354 shares of the company's stock worth $1,108,000 after buying an additional 800 shares during the period. Intech Investment Management LLC increased its stake in shares of CONMED by 34.6% in the first quarter. Intech Investment Management LLC now owns 22,505 shares of the company's stock worth $1,359,000 after buying an additional 5,780 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of CONMED by 5.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 82,686 shares of the company's stock worth $4,993,000 after buying an additional 4,565 shares during the period.

About CONMED

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries.